<code id='0726B91638'></code><style id='0726B91638'></style>
    • <acronym id='0726B91638'></acronym>
      <center id='0726B91638'><center id='0726B91638'><tfoot id='0726B91638'></tfoot></center><abbr id='0726B91638'><dir id='0726B91638'><tfoot id='0726B91638'></tfoot><noframes id='0726B91638'>

    • <optgroup id='0726B91638'><strike id='0726B91638'><sup id='0726B91638'></sup></strike><code id='0726B91638'></code></optgroup>
        1. <b id='0726B91638'><label id='0726B91638'><select id='0726B91638'><dt id='0726B91638'><span id='0726B91638'></span></dt></select></label></b><u id='0726B91638'></u>
          <i id='0726B91638'><strike id='0726B91638'><tt id='0726B91638'><pre id='0726B91638'></pre></tt></strike></i>

          focus

          focus

          author:fashion    Page View:729
          Richard Neal(D-MA), Rep. Frank Pallone (D-NJ),Rep. John Yarmuth (D-KY), Rep. Bobby Scott (D-VA) and House Minority Leader Nancy Pelosi (D-CA) attend the weekly press conference in the Capitol building on July 20, 2017 in Washington, DC. They spoke to the media about the efforts to reform the health care bill. -- health policy coverage from STAT
          Reps. Richard Neal (D-Mass.), Rep. Frank Pallone (D-N.J.), and Rep. John Yarmuth (D-Ky.) Joe Raedle/Getty Images

          WASHINGTON — It’s drug pricing déjà vu: Just as they did in 2019, House Democrats are pushing a bill that would allow Medicare to negotiate dozens of drug prices a year, offer those prices to all insurers, and crack down on price hikes.

          Unlike then, Democrats have a starting place: the new bill represents an expansion of the major drug pricing legislation the party passed last year. But the first round of drug price negotiations hasn’t even started yet, and the law is under attack from the pharmaceutical industry in court.

          advertisement

          The Democratic leaders of three key House committees put forth the proposal Wednesday.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs
          Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

          LongtimeBluebirdBioCEONickLeschlyWendyMaeda/TheBostonGlobeSometwoyearsaftersplittingbiotechcompanyBl

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          White House touts steps to stem shortages of cancer treatments

          TheWhiteHouseoutlineditseffortstoendshortagesofthreekeygenericchemotherapies.Butexpertswantmoremored